Recent advances in therapeutic strategies for triple-negative breast cancer

• Published in: Journal of hematology and oncology Vol. 15; no. 1; pp. 1 - 121
• Main Authors: Li, Yun, Zhang, Huajun, Merkher, Yulia, Chen, Lin, Liu, Na, Leonov, Sergey, Chen, Yongheng
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 29.08.2022; BioMed Central; BMC
• Subjects: Androgen receptors; Androgens; Antimitotic agents; Antineoplastic agents; Breast cancer; Cancer; Cancer therapies; Cell cycle; Chemotherapy; Combination therapy; Cyclin-dependent kinases; Development and progression; DNA damage; DNA repair; Gene expression; Genetic aspects; Genomes; Growth factors; Health aspects; Hematology; Immunotherapy; Kinases; Medical prognosis; Metastasis; Mortality; Mutation; Oncology; Prognosis; Radiation therapy; Review; Signal transduction; Targeted therapy; Triple-negative breast cancer; Canada
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-022-01341-0

Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Hence, targeted therapies, such as those targeting DNA repair pathways, androgen receptor signaling pathways, and kinases, represent promising treatment options against TNBC. In addition, immunotherapy has also been demonstrated to improve overall survival and response in TNBC. In this review, we summarize recent key advances in therapeutic strategies based on molecular subtypes in TNBC.